ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.

I. Kim,1 J. Choi,1 A. Vo,1 A. Kang,1 M. Toyoda,1 J. Mirocha,2 E. Kamil,1 S. Louie,1 O. Galera,1 S. Jordan,1 D. Puliyanda.1

1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
2Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.

Meeting: 2016 American Transplant Congress

Abstract number: D152

Keywords: Alloantigens, Highly-sensitized, Kidney transplantation, Pediatric

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Kidney-Pediatrics

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Thymoglobulin Is Safe and Effective as Induction Therapy for Early Steroid Withdrawal in Pediatric Renal Transplantation
  • Induction With an Interleukin-2 Receptor Antagonist in Sensitized Adult Kidney Transplant Recipients Is Highly Effective and Safe

Introduction: Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well-tolerated in pediatric renal transplantation. We report on the use of alemtuzumab induction in HS pediatric kidney transplant.

Methods: 50 renal transplants were performed from 1/2009-12/2014. 15 HS patients received IVIg/Rituximab for desensitization with alemtuzumab induction (15-30mg, 1 dose), while 35 nonsensitized patients received anti-IL-2R (2 doses). Graft survival and infections were compared between 2 groups.

Results: All HS patients had received a prior transplant and were older. Patient survival was 100% and graft outcomes were similar with mean 1-year creatinine of 1.03±0.45 vs. 0.99±0.6, p=0.48. White blood cell (WBC) and absolute lymphocyte count (ALC) were significantly lower in alemtuzumab group at 30 days, p<0.0001, and at 1 year, p=0.026 and p=0.001, respectively. There was no significant difference in bacterial, viral (viremia defined as >50 copies/PCR), or fungal infections over 5 years.

Conclusions: Alemtuzumab induction with desensitization was well-tolerated and effective in HS pediatric patients. Although significant suppression of WBC and ALC up to 1 year post-transplant was observed, there was no significant increase in infections.

Variable Alemtuzumab (N=15) Percent IL-2R (N=35) Percent P-Value
Age, Median (IQR) 18 (14 – 19)   14 (5 – 17)   0.012
Sex  Female  40  Female 51.4 0.54
Living Donor 1 6.7 3 8.6  
           
Serum creatinine 12 months 1.03±0.45   0.99±.60   0.48
WBC          
Day 30 4.30±2.17   9.28±3.22   < 0.0001
Day 365 5.76±2.63   8.07±2.44   0.026
ALC          
Day 30 0.15±0.16   3.94±2.26   < 0.0001
Day 365 1.49±2.12   2.97±1.24   0.001
           
Infections          
Bacterial 7 46.7 19 54.2 NS
Fungal 0   0    
Viral 3 20 12 34.2 NS

CITATION INFORMATION: Kim I, Choi J, Vo A, Kang A, Toyoda M, Mirocha J, Kamil E, Louie S, Galera O, Jordan S, Puliyanda D. Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kim I, Choi J, Vo A, Kang A, Toyoda M, Mirocha J, Kamil E, Louie S, Galera O, Jordan S, Puliyanda D. Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/alemtuzumab-is-safe-and-effective-induction-therapy-in-highly-sensitized-hs-pediatric-patients-undergoing-transplantation/. Accessed March 2, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.